Poly drug use,chemsex drug use,and associations with sexual risk behaviour in HIV-negative men who have sex with men attending sexual health clinics |
| |
| Affiliation: | 1. Research Department of Infection & Population Health, University College London, London, United Kingdom;2. Chelsea and Westminster Hospital NHS Foundation Trust, London, United Kingdom;3. Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom;4. HIV i-Base, London, United Kingdom;5. City, University of London, London, United Kingdom;1. Centre d’évaluation et d’information sur la pharmacodépendance (CEIP), centre d’addictovigilance Île-de-France, centre Val-de-Loire, hôpital Fernand-Widal, AP–HP, 200, rue du Faubourg-Saint-Denis, 75475 Paris cedex 10, France;2. Unité fonctionnelle de toxicologie, CHU de Lille, 59000 Lille, France;3. EA 4483–IMPECS–IMPact de l’environnement chimique sur la santé humaine, University of Lille, 59000 Lille, France;4. Centres d’accueil et d’accompagnement à la réduction des risques chez les usagers de drogues (CAARUD) AIDES, Les Halles, 75002 Paris, France;5. Observatoire français des drogues et des toxicomanies (OFDT), 93200 Saint-Denis, France;6. Hôpital Marmottan, 75017 Paris, France;7. Clinique Montévidéo, 92100 Boulogne-Billancourt, France;1. Toxicology Unit, Imperial College London, St. Dunstan’s Road, London W6 8RP, UK;2. Section of Endocrinology and Investigative Medicine, Imperial College London, Commonwealth Building, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK;1. Sigma Research, Department of Social & Environmental Health Research, London School of Hygiene & Tropical Medicine, United Kingdom;2. Department of Global Health and Development, London School of Hygiene & Tropical Medicine, United Kingdom;3. Department of Public Health, London Borough of Lambeth, United Kingdom;1. Hertfordshire Sexual Health, Chelsea and Westminster NHS Foundation Trust, United Kingdom;2. HIV & STI Department, Centre for Infectious Disease Surveillance and Control (CIDSC), Public Health England, London, United Kingdom;3. Chelsea and Westminster Hospital NHS Foundation Trust, United Kingdom;4. CNWL, Imperial College London, United Kingdom;5. Centre for Molecular Epidemiology and Translational Research, Institute for Global Health, UCL, London, United Kingdom;6. Department of HIV and STIs, National Infection Service, Public Health England, 61 Colindale Avenue, London, NW9 5EQ, United Kingdom;1. Rutgers School of Public Health, Rutgers University, Center for Health, Identity, Behavior & Prevention Studies (CHIBPS), RWJ Medical School, Rutgers University, Graduate School of Applied and Professional Psychology, Rutgers University, School of Public Affairs and Administration, Rutgers University, United States;2. Center for Health, Identity, Behavior & Prevention Studies (CHIBPS), United States;1. Sigma Research, London School of Hygiene and Tropical Medicine, United Kingdom;2. Swiss Federal Office of Public Health, Bern, Switzerland;3. Robert Koch Institute, Berlin, Germany |
| |
| Abstract: | BackgroundRecreational drug use and associated harms continue to be of significant concern in men who have sex with men (MSM) particularly in the context of HIV and STI transmission.MethodsData from 1484 HIV-negative or undiagnosed MSM included in the AURAH study, a cross-sectional, self-completed questionnaire study of 2630 individuals from 20 sexual health clinics in the United Kingdom in 2013–2014, was analysed. Two measures of recreational drug use in the previous three months were defined; (i) polydrug use (use of 3 or more recreational drugs) and (ii) chemsex drug use (use of mephedrone, crystal methamphetamine or GHB/GBL). Associations of socio-demographic, health and lifestyle factors with drug use, and associations of drug use with sexual behaviour, were investigated.ResultsOf the 1484 MSM, 350 (23.6%) reported polydrug use and 324 (21.8%) reported chemsex drug use in the past three months. Overall 852 (57.5%) men reported condomless sex in the past three months; 430 (29.0%) had CLS with ≥2 partners, 474 (31.9%) had CLS with unknown/HIV+ partner(s); 187 (12.6%) had receptive CLS with an unknown status partner. For polydrug use, prevalence ratios (95% confidence interval) for association with CLS measures, adjusted for socio-demographic factors were: 1.38 (1.26, 1.51) for CLS; 2.11 (1.80, 2.47) for CLS with ≥2 partners; 1.89 (1.63, 2.19) for CLS with unknown/HIV+ partner(s); 1.36 (1.00, 1.83) for receptive CLS with an unknown status partner. Corresponding adjusted prevalence ratios for chemsex drug use were: 1.38 (1.26, 1.52); 2.07 (1.76, 2.43); 1.88 (1.62, 2.19); 1.49 (1.10, 2.02). Polydrug and chemsex drug use were also strongly associated with previous STI, PEP use, group sex and high number of new sexual partners. Associations remained with little attenuation after further adjustment for depressive symptoms and alcohol intake.ConclusionThere was a high prevalence of polydrug use and chemsex drug use among HIV negative MSM attending UK sexual health clinics. Drug use was strongly associated with sexual behaviours linked to risk of acquisition of STIs and HIV. |
| |
| Keywords: | Recreational drug use Chemsex Sexual behaviour HIV negative Men who have sex with men Sexual health HIV prevention |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
